Quick Links

Hydroxychloroquine for COVID-19 PEP

Hydroxychloroquine for COVID-19 PEP

Post-exposure prophylaxis (PEP) is defined as taking antimicrobial medication after being exposed or potentially exposed to an infectious agent to prevent becoming infected. PEP is routinely used for prevention of a variety of viral, bacterial, and parasitic infections, including influenza and human immunodeficiency virus (HIV).

This is a randomized, multi-center, placebo-equivalent (ascorbic acid) controlled, blinded study of hydroxychloroquine (HCQ) PEP for the prevention of COVID-19 infection in adults exposed to the coronavirus. This study will enroll up to 2,000 men and women who meet the eligibility criteria from multiple sites in the United States.

Volunteers who participate in the study will be asked to take a medication (either HCQ or vitamin C), complete an online survey to assess their symptoms, and collect a sample by swabbing the inside of their nose every day for 14 days. On Day 28 a final swab will be collected and a survey completed. Volunteers will be in the study for approximately 28 days.

**If you are interested in participating, please visit: https://depts.washington.edu/covid19pep/
Directly click on the link on the right marked “Contact for More Information” and complete the pre-screening form.**

Participant Eligibility

– Men or women 18 to 80 years of age inclusive, at the time of signing the informed consent
– Had close contact* of a person (index) with known PCR-confirmed SARS-CoV-2 infection or index who is currently being assessed for COVID-19
*Close contact is defined as:
a. Household contact
b. Medical staff, first responders, or other care persons who cared for the index case without personal protection (mask and gloves)
– Less than 4 days since last exposure (close contact with a person with SARS-CoV-2 infection)
– Access to device and internet for Telehealth visits


UW COVID-19 PEP team
(206) 520-4366


Additional Study Details

Full Study Title
Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): A Blinded, Randomized Study

Study ID: STUDY00009750
Start Date: 03/20/2020
End Date: 03/20/2021

Dr. Ruanne V. Barnabas, University of Washington
Dr. Anna Bershteyn, NYU School of Medicine

Accepts Healthy Volunteers?

Study Site(s)

University of Washington

908 Jefferson Street 11NJ1166
Seattle, Washington 98104



Use the link below to send a message to the study coordinator, or call the number above to speak directly with a study representative.

I am interested in this research study.